B
Bullisch
Bullisch · 25%NBIX
$166.71
Szenariopreis
$135.910
+0.788 (+0.58%)Zum Schluss
Loading chart…
- Hoch
- 136.570
- Eröffnung
- 133.940
- Volumengewichteter Durchschnittskurs
- 134.91
- Volumen
- 1.51M
- Marktkap.
- 13.52B
- Tief
- 132.250
- Umsatz
- 203.27M
- EV/EBITDA, TTM
- 13.00
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others.
KI-Analyse of Neurocrine Biosciences, Inc (NBIX)
KaufenNeurocrine Biosciences Inc is a good buy right now due to its current price of $142.44, which is significantly below the average analyst price target of $221, suggesting a potential upside of 55%. Additionally, the forward P/E ratio of 14.12 indicates attractive valuation compared to its growth prospects. However, the main risk is the safety concerns surrounding the VYKAT XR acquisition, which has led to a 25% pullback in stock price since Q2.
Analystenbewertungen (13)
+32.21% Aufwärtspotenzial
Kaufen
13 Kaufen
0 Halten
0 Verkaufen
Aktuell: 135.91
Tief
143.00
Durchschnitt
179.68
Hoch
203.00
BMO Capital
Market Perform
$150
2026-10-12
BMO Capital
2026-10-12
Kursziel
$150
Market Perform
Guggenheim
Kaufen
$207
2026-10-05
Guggenheim
2026-10-05
Kursziel
$207
Kaufen
UBS
Kaufen
$214
2026-09-29
UBS
2026-09-29
Kursziel
$214
Kaufen
Morgan Stanley
Equal Weight
$183
2026-09-11
Morgan Stanley
2026-09-11
Kursziel
$183
Equal Weight
Citi
Kaufen
$253
2026-09-03
Citi
2026-09-03
Kursziel
$253
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Neurocrine Biosciences, Inc (NBIX) beträgt 14.12, verglichen mit dem 5-Jahres-Durchschnitt von 20.53.
Alphio-AI-Kursszenarien für NBIX
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die NBIX halten
Event-Zeitleiste
News
1.010-12PRnewswireNeurocrine Biosciences Schedules Q3 2026 Earnings Call
8.509-30PRnewswireNeurocrine Advances Research on Prader-Willi Syndrome at FPWR Symposium
8.509-30NewsfilterNeurocrine Advances Research on Prader-Willi Syndrome with VYKAT XR Studies
5.009-29NASDAQ.COMNeurocrine Appoints New Chief Medical Officer
5.009-28PRnewswireNeurocrine Appoints New Chief Medical Officer
NBIX FAQ – beantwortet von Alphio AI
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Neurocrine Biosciences Inc is a good buy right now due to its current price of $142.44, which is significantly below the average analyst price target of $221, suggesting a potential upside of 55%. Additionally, the forward P/E ratio of 14.12 indicates attractive valuation compared to its growth prospects. However, the main risk is the safety concerns surrounding the VYKAT XR acquisition, which has led to a 25% pullback in stock price since Q2.
13 analysts cover NBIX: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 179.68.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.